Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Nurix Therapeutics, Inc. (NRIX) due to higher revenues, with a focus on how actual results will compare to estimates [1][3]. Earnings Expectations - The consensus estimate predicts a quarterly loss of $0.70 per share, reflecting a year-over-year change of +1.4% [3][19]. - Expected revenues are $19.81 million, which represents a significant increase of 63.9% from the same quarter last year [3][19]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4][19]. - The Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +4.74%, suggesting a bullish outlook from analysts [12][19]. Earnings Surprise Potential - A positive Earnings ESP reading indicates a higher likelihood of an earnings beat, especially when combined with a Zacks Rank of 2 (Buy) [10][12]. - Nurix Therapeutics has a Zacks Rank of 2, enhancing the probability of surpassing the consensus EPS estimate [12][20]. Historical Performance - In the last reported quarter, Nurix Therapeutics was expected to post a loss of $0.72 per share but actually reported a loss of -$0.67, resulting in a surprise of +6.94% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14].